# Envisagenics

> Envisagenics is a New York biotechnology company using its proprietary SpliceCore AI platform to identify disease-specific RNA splicing targets. It combines computational discovery with experimental validation, works with biopharma and academic partners, and develops its own oncology and neurodegenerative-disease programs.

- **Founded:** 2014
- **Headquarters:** New York, United States
- **Founders:** Maria Luisa Pineda (CEO and co-founder), Martin Akerman (CTO and co-founder)
- **Products:** SpliceCore®, SpliceIO™, Discovery and validation collaborations, ENV-375
- **Notable:** Spin-out from Cold Spring Harbor Laboratory, founded in 2014., North American winner of the 2018 Innovate.AI competition, receiving a $1 million investment., Peer-reviewed 2024 Molecular Systems Biology study on AI/ML-derived splice-switching oligonucleotides.

## Products & services

- **SpliceCore®** — Proprietary cloud-based AI platform for identifying and prioritizing disease-specific alternative splicing events, therapeutic targets and biomarkers from RNA-sequencing data.
- **SpliceIO™** — Machine-learning module for identifying tumor-specific RNA splicing-derived neoepitopes for immunotherapy development.
- **Discovery and validation collaborations** — Research programs with biopharma and academic institutions combining RNA data analysis, target prioritization and experimental validation.
- **ENV-375** — Wholly owned antisense oligonucleotide program for ALS, described in September 2026 as late-stage preclinical.

## Achievements

- Spin-out from Cold Spring Harbor Laboratory, founded in 2014.
- North American winner of the 2018 Innovate.AI competition, receiving a $1 million investment.
- Peer-reviewed 2024 Molecular Systems Biology study on AI/ML-derived splice-switching oligonucleotides.
- Public research collaborations spanning oncology and CNS disease.
- September 2026 Boehringer agreement with more than $1 billion in potential payments plus royalties.

## Latest updates

- **2026-09** — Announced a multi-target oncology collaboration and option agreement with Boehringer Ingelheim; identified ENV-375 as late-stage preclinical.
- **2024-07** — Announced former Eli Lilly departmental CSO Kalpana Merchant joining the board.
- **2024-06** — Announced Series B funding with Bristol Myers Squibb joining as a strategic investor.
- **2024-04** — Published AI/ML-derived splice-switching oligonucleotide research in Molecular Systems Biology.

## Links

- Website: https://www.envisagenics.com/
- LinkedIn: https://www.linkedin.com/company/envisagenics/
- Twitter/X: https://twitter.com/envisagenics
- YouTube: https://www.youtube.com/channel/UCyzyw9O8KRUPOcDeyzu80Sg
- Facebook: https://facebook.com/envisagenicsinc

---

Profile page: https://yespress.io/envisagenics
Published by YesPress — https://yespress.io
Last updated: 2026-10-05